DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Biogen - 1 Dr - 1 Alberto Espay - 1 Espay - 1 Ivan Cheung - 1 CNBC's - 1 Cheung - 1 Ivan Cheung Ivan Cheung - 1
Top related locs:
Tokyo Japan Eisai
Top related orgs:
Eisai U.S - 2 Bloomberg - 1 Getty - 1 U.S - 1 . Food - 1 Medicare - 1 University of Cincinnati College of - 1 NBC News - 1

Search resuls for: "Eisai U.S"


5 mentions found


☆ Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
  + stars: | 2023-07-07 | by ( Jihye Lee Anmar Frangoul | Jihye Lee | Anmar Frangoul | ) www.cnbc.com   time to read: +1 min
Signage for Eisai Co. at the company's headquarters in Tokyo, Japan, on Friday, Feb. 3, 2023. Bloomberg | Bloomberg | Getty ImagesShares of Japanese pharmaceutical giant Eisai sank Friday after the company's Alzheimer's drug was formally approved by U.S. regulators overnight, prompting questions over investor sentiment surrounding the move. Eisai shares closed 4.67% lower after paring some of its earlier losses. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. "The odds for brain swelling and hemorrhage are far higher than any actual improvement," Espay, who launched a petition in June calling for the Alzheimer's treatment to not get full approval, told NBC News.
Persons: Biogen, Dr, Alberto Espay, Espay, Ivan Cheung, CNBC's, Cheung Organizations: Bloomberg, Getty, U.S, . Food, Medicare, University of Cincinnati College of, NBC News, Eisai U.S Locations: Tokyo, Japan, Eisai
☆ Many health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan Cheung
  + stars: | 2023-07-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMany health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan CheungIvan Cheung, Eisai U.S. CEO, joins 'Fast Money' to discuss the FDA approving Biogen's 'Leqembi' Alzheimer's drug.
Persons: Ivan Cheung Ivan Cheung Organizations: Eisai U.S
☆ Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi
  + stars: | 2023-02-23 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +6 min
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Due to the drug's high price and Medicare's coverage restrictions, seniors are unable to access the treatment. The letter the Alzheimer's Association sent to CMS in December calling for unrestricted coverage was signed by more than 200 researchers and experts. CMS said it would provide broader coverage of Leqembi on the same day should the FDA fully approve the treatment. Medicare adopted the coverage restrictions after controversy over the Alzheimer's antibody treatment Aduhelm, which was also developed by Eisai and Biogen.
☆ CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval
  + stars: | 2023-01-06 | by ( Melissa Lee | ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approvalCNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mathisen and the Fast Money traders, Tim Seymour, Bonawyn Eison, Steve Grasso and Jeff Mills.
☆ We believe the risk-benefit profile for our Alzheimer's drug is acceptable, says Eisai U.S. CEO
  + stars: | 2022-11-30 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe believe the risk-benefit profile for our Alzheimer's drug is acceptable, says Eisai U.S. CEOIvan Cheung, Eisai U.S. CEO, joins 'Closing Bell' to discuss the results of Eisai's experimental Alzheimer's phase three trial, the side effects associated with the Alzheimer's drug and more.
0 next >>
Total: 5